Compare BENF & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BENF | BTMD |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.6M | 64.4M |
| IPO Year | N/A | 2021 |
| Metric | BENF | BTMD |
|---|---|---|
| Price | $4.68 | $2.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 516.9K | 140.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.68 |
| Revenue | N/A | ★ $197,191,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $93.54 | $2.37 |
| P/E Ratio | ★ N/A | $3.18 |
| Revenue Growth | N/A | ★ 6.38 |
| 52 Week Low | $0.22 | $2.02 |
| 52 Week High | $9.96 | $4.75 |
| Indicator | BENF | BTMD |
|---|---|---|
| Relative Strength Index (RSI) | 53.86 | 44.88 |
| Support Level | $3.99 | $2.02 |
| Resistance Level | $5.21 | $2.37 |
| Average True Range (ATR) | 0.58 | 0.10 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 70.78 | 44.44 |
Beneficient is a technology-enabled financial services holding company that (together with its subsidiaries) provides simple, rapid, and cost-effective liquidity solutions to participants in the alternative asset industry through its end-to-end online platform, AltAccess. BCG's products and services are designed to meet the unmet needs of mid-to-high net-worth individual investors, small-to-midsize institutional investors, family offices, and fund general partners. Its bespoke liquidity solutions for otherwise illiquid alternative asset investments are delivered through proprietary technology and a financing and trust structure. It has three reportable segments consisting of Ben Liquidity, Ben Custody and Customer ExAlt Trusts.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.